Product Certification&
    Enterprise Certification

  • Mr.simon
    Tel: 86-021-58380978

  • Ms.Cecilia Wei
    Tel: 021-58380978

  • Mobile:13482386415
  • Tel:86-021-58380978
  • Fax:86-021-58380977
  • URL:http://www.systeambc.com
  • Province/state:shanghai
  • City:shanghai
  • Street:Building 87,Lane 669, Dong Jing Road Shanghai,P.R.China
  • MaxCard:
Home > Products >  AZD-9291 mesylate

AZD-9291 mesylate CAS NO.1421373-66-1

  • FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
  • Min.Order: 100 Gram
  • Payment Terms: L/C
  • Available Specifications:

    ≥98.0%(100-500)Gram≥98.0%(1000-5000)Gram

  • Product Details

Keywords

  • 1421373-66-1
  • AZD-9291 mesylate
  • AZD-9291 (Mesylate);N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate (1:1);AZD-9291 mesylate N-[2-[[2-(Dim

Quick Details

  • ProName: AZD-9291 mesylate
  • CasNo: 1421373-66-1
  • Molecular Formula: C28H33N7O2.CH4O3S
  • Appearance: White crystal
  • Application: Pharmaceutical intermediates. Fine che...
  • DeliveryTime: 2 months
  • PackAge: 100g,500g,1kg,25kg
  • Port: shang hai
  • ProductionCapacity: 1000 Gram/Month
  • Purity: ≥98.0%
  • Storage: Dry seal
  • Transportation: shipping
  • LimitNum: 100 Gram

Superiority

We are specialized in custom synthesis, chemical/pharmaceutical/ pesticides outsourcing and contract research.
 
 
 
We are committed to provide excellence in researching, manufacturing and drug discovery process.
 
 
 
Our research team of scientists consists of western-trained Ph.D.s with experience and capabilities in drug R&D methodologies and medicinal chemistry.

 

Details

AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM).
IC50 value: 12.92 nM(Exon 19 deletion EGFR); 11.44 nM(L858R/T790M EGFR) [1]
Target: L858R/T790M EGFR; Exon 19 deletion EGFR
AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines.
Patent: WO 2013014448

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog